Adherence to the major classes of anthypertensive theraphy (AMCA)

Study identification

• EU PAS number:
  EUPAS50008
• Study ID:
  50272
• Official title and acronym:
  Adherence to the major classes of anthypertensive theraphy (AMCA)
• DARWIN EU® study:
  No
• Study countries:
  Sweden
• Study description:
  Using the trial emulation method, an observational database of all Swedish residents ≥ 40 years of age starting antihypertensive therapy for the first time in a single pill between 2011 and 2018 will be analyzed. By cross referencing 4 national all-covering registers we will create an observational database of people initiating antihypertensive therapy in a setting of universal healthcare with negligible co-payment. The target trial emulation method will be used to create an observational study with minimal bias. Persistence on class and therapy level will be determined by following consequently retrieved prescriptions and calculating proportion of days covered. A multi-state framework will then be used were the patients are allowed to go back and forth between on (periods ≥ 80 % of treatment days covered) and off periods (periods <80 % of treatment days covered), with the addition of the absorbing states; death or cardiovascular event.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Uppsala University

Study timelines

Date when funding contract was signed

Planned: 01/02/2022

Actual: 01/02/2022

Study start date

Planned: 26/06/2020

Actual: 26/06/2020

Data analysis start date

Planned: 28/01/2022

Actual: 10/01/2024

Date of final study report

Planned: 28/04/2023

Sources of funding

Other

More details on funding

Primary Care and Health, Region Uppsala, Sweden

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable